Perelel Secures $27 Million Growth Investment to Expand Women’s Health Supplement Brand
Perelel, the doctor-founded women’s health supplement company focused on tailored nutrition across the hormonal lifecycle, has secured a $27 million growth investment as it transitions from a leading prenatal brand into a broader women’s wellness leader. The funding round, announced in November 2025, represents the most significant external capital the Los Angeles-based company has raised to date as it seeks to expand distribution, broaden product offerings, and strengthen its position in the growing women’s health market.
The growth equity round was led by Prelude Growth Partners, a consumer-focused investment firm that partners with high-potential brands across health, wellness, beauty, and lifestyle categories. Prelude’s participation marks its first institutional investment in Perelel and reflects confidence in the company’s clinical rigor, differentiated brand positioning, and strong business momentum. Existing investors Unilever Ventures, Willow Growth Partners and Selva Ventures also participated in the round, reinforcing long-term support for the company’s mission and growth strategy.
Founded in 2020 by co-CEOs Victoria Thain Gioia and Alex Taylor together with OB-GYN Dr. Banafsheh Bayati, Perelel has built its reputation on scientifically backed, clinically supported supplements designed to meet women’s needs from fertility and pregnancy to postpartum and perimenopause. The company’s products are formulated to address distinct hormonal life stages with the aim of delivering clarity and trusted solutions in a historically under-researched segment of health and wellness.
In its first five years, Perelel has achieved profitability, doubled its annual revenue year-over-year, and maintained strong subscriber retention, highlighting both consumer demand and the effectiveness of its targeted supplement offerings. The brand also expanded significantly beyond its initial prenatal focus, launching over 20 products and broadening its reach into markets that include perimenopause and broader women’s wellness. Perelel’s supplements are available through a combination of direct-to-consumer channels and retail partners, giving the company a diversified distribution base as it scales nationally.
The latest funding will enable Perelel to accelerate distribution expansion, invest in product innovation and clinical validation, and enhance its operational capabilities as it pursues long-term growth objectives. The partnership with Prelude Growth Partners also brings strategic support and expertise in scaling consumer brands, particularly those at the intersection of wellness and lifestyle—a combination that aligns with Perelel’s broader mission to reimagine women’s health solutions.
Prelude Growth Partners’ entry into Perelel’s cap table follows a shift in investor dynamics, where early angel backers were able to realize returns while enabling the company to bring in a partner positioned to support its next stage of expansion. Prelude’s co-founding partner Neda Daneshzadeh emphasized the brand’s clinical grounding and commitment to women’s health research as core differentiators that made Perelel an attractive investment opportunity.
Perelel’s growth trajectory reflects broader trends in the women’s health and wellness sector, where demand for science-based, stage-specific products continues to rise. As consumers increasingly seek evidence-backed solutions tailored to their unique physiological needs, brands like Perelel that combine clinical expertise with targeted nutrition are gaining traction. The company’s emphasis on rigorous research and its comprehensive approach across multiple hormonal life stages distinguish it in a crowded wellness landscape where many products lack medical validation.
Beyond product development, Perelel has also made strategic investments in community and education, advocating for improved women’s health research and literacy. This focus resonates with customers who value transparency and scientifically grounded health solutions, reinforcing the brand’s authenticity and long-term growth potential as it continues to build trust with a loyal consumer base.
The $27 million growth investment positions Perelel to further solidify its leadership in women’s health supplements and deepen its impact across the hormonal lifecycle market. With strong investor backing and a clear strategic vision, the company is poised to expand its footprint within an emerging segment of health and wellness that bridges clinical credibility with everyday consumer needs. As the women’s wellness category continues to attract attention from investors and consumers alike, Perelel’s momentum underscores the growing appetite for products that are not only effective but also grounded in scientific expertise.
